Market overview
The global canine fungal infection treatment market is worth USD 159 mn in 2026 and is forecast to reach USD 272 mn by 2036, growing at a 5.5% CAGR. United States is the largest country market and Azole antifungals is the largest by drug type segment.
| Scope | Antifungal medicines for dogs: oral azoles, medicated shampoos, wipes and topical treatments for skin, ear and systemic fungal infections. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 150 mn |
| Value 2026 | USD 159 mn |
| Value 2036 | USD 272 mn |
| CAGR 2026-2036 | 5.5% |
| Volume 2026 | 14.7 million treatment courses |
| Volume 2036 | 22.7 million treatment courses |
| Average price 2026 | USD 10.8 per treatment course |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Canine Fungal Infection Treatment market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 159 mn |
| 2027 | USD 168 mn |
| 2028 | USD 177 mn |
| 2029 | USD 187 mn |
| 2030 | USD 197 mn |
| 2031 | USD 208 mn |
| 2032 | USD 219 mn |
| 2033 | USD 231 mn |
| 2034 | USD 244 mn |
| 2035 | USD 257 mn |
| 2036 | USD 272 mn |
Canine Fungal Infection Treatment market segmentation
By drug type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Azole antifungals | 42.0% | 39.6% | USD 67 mn | 4.9% |
| Medicated shampoos and washes | 30.0% | 31.1% | USD 48 mn | 5.9% |
| Topical creams and wipes | 20.0% | 21.7% | USD 32 mn | 6.4% |
| Other antifungals | 8.0% | 7.5% | USD 13 mn | 4.9% |
By route
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Topical | 54.0% | 56.5% | USD 86 mn | 6.0% |
| Oral | 42.0% | 40.0% | USD 67 mn | 5.0% |
| Injectable | 4.0% | 3.5% | USD 6.4 mn | 4.0% |
By fungal infection
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Dermatophytosis | 34.0% | 33.0% | USD 54 mn | 5.2% |
| Malassezia dermatitis | 30.0% | 30.0% | USD 48 mn | 5.5% |
| Yeast and candidiasis | 14.0% | 14.0% | USD 22 mn | 5.5% |
| Systemic fungal | 22.0% | 23.0% | USD 35 mn | 6.0% |
By infection site
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Skin and coat | 56.0% | 54.0% | USD 89 mn | 5.1% |
| Ears | 20.0% | 20.0% | USD 32 mn | 5.5% |
| Nails and paws | 12.0% | 13.0% | USD 19 mn | 6.3% |
| Internal organs | 12.0% | 13.0% | USD 19 mn | 6.3% |
By dosage form
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Shampoos and washes | 28.0% | 25.0% | USD 45 mn | 4.3% |
| Tablets | 34.0% | 34.0% | USD 54 mn | 5.5% |
| Topical creams | 22.0% | 21.0% | USD 35 mn | 5.0% |
| Injectables | 16.0% | 20.0% | USD 25 mn | 7.9% |
Top 25 countries for canine fungal infection treatment by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 86.0% of 2026 revenue and the 25 countries below together hold 95.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 60 mn | 38.0% | USD 101 mn | 5.3% |
| 2 | Germany | USD 11 mn | 7.0% | USD 18 mn | 4.9% |
| 3 | United Kingdom | USD 11 mn | 7.0% | USD 18 mn | 4.9% |
| 4 | France | USD 9.5 mn | 6.0% | USD 15 mn | 4.8% |
| 5 | Brazil | USD 9.5 mn | 6.0% | USD 18 mn | 6.8% |
| 6 | China | USD 9.5 mn | 6.0% | USD 22 mn | 8.8% |
| 7 | Japan | USD 8.0 mn | 5.0% | USD 13 mn | 4.8% |
| 8 | Italy | USD 6.4 mn | 4.0% | USD 10 mn | 4.7% |
| 9 | Australia | USD 5.6 mn | 3.5% | USD 9.2 mn | 5.2% |
| 10 | Canada | USD 5.6 mn | 3.5% | USD 9.2 mn | 5.2% |
| 11 | Netherlands | USD 1.8 mn | 1.1% | USD 2.9 mn | 4.8% |
| 12 | Spain | USD 1.8 mn | 1.1% | USD 2.8 mn | 4.7% |
| 13 | Belgium | USD 1.7 mn | 1.1% | USD 2.7 mn | 4.7% |
| 14 | Mexico | USD 1.5 mn | 1.0% | USD 2.8 mn | 6.0% |
| 15 | Russia | USD 1.4 mn | 0.9% | USD 2.5 mn | 6.0% |
| 16 | Argentina | USD 1.2 mn | 0.8% | USD 2.2 mn | 6.0% |
| 17 | South Korea | USD 1.1 mn | 0.7% | USD 2.0 mn | 6.0% |
| 18 | Poland | USD 0.97 mn | 0.6% | USD 1.7 mn | 6.0% |
| 19 | India | USD 0.86 mn | 0.5% | USD 1.6 mn | 6.1% |
| 20 | Sweden | USD 0.67 mn | 0.4% | USD 1.1 mn | 4.7% |
| 21 | Switzerland | USD 0.54 mn | 0.3% | USD 0.87 mn | 4.9% |
| 22 | Denmark | USD 0.48 mn | 0.3% | USD 0.76 mn | 4.8% |
| 23 | Turkey | USD 0.45 mn | 0.3% | USD 0.81 mn | 6.2% |
| 24 | Colombia | USD 0.43 mn | 0.3% | USD 0.76 mn | 5.9% |
| 25 | Austria | USD 0.43 mn | 0.3% | USD 0.68 mn | 4.7% |
| Rest of world | USD 6.9 mn | 4.3% | USD 11 mn | 4.9% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Elanco
- Zoetis
- Virbac
- Dechra
- Merck Animal Health
Group 2: Regional and specialist players
- Vetoquinol
- Ceva
- Boehringer Ingelheim
- Norbrook
- Ecuphar
- Sogeval
- Dermcare-Vet
Group 3: Emerging and niche players
- Bimeda
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the canine fungal infection treatment market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.
The market is divided by drug type, by route, by fungal infection, by infection site, by dosage form. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the canine fungal infection treatment market?
The global canine fungal infection treatment market is estimated at USD 150 mn in 2025 and USD 159 mn in 2026.
How fast will the canine fungal infection treatment market grow?
It is forecast to reach USD 272 mn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 113 mn.
Which country is the largest market for canine fungal infection treatment?
United States is the largest market by revenue at USD 60 mn in 2026, 38.0% of the global total. The three largest countries together hold 52.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 8.8% a year from 2026 to 2036.
Which canine fungal infection treatment segment is largest?
In the by drug type split, Azole antifungals is the largest segment with 42.0% of 2026 revenue.
Who are the leading canine fungal infection treatment companies?
Global leaders include Elanco, Zoetis, Virbac, Dechra.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Immunoadsorption ColumnsUSD 160 mn · 6.5% CAGR
- Protein-Free Nutrition ModuleUSD 160 mn · 6.5% CAGR
- Dermatology Cryosurgery UnitsUSD 158 mn · 5.0% CAGR
- Theranostic Workflow PlatformsUSD 156 mn · 18.0% CAGR
- AI-Powered Gait & Mobility AnalyticsUSD 151 mn · 11.0% CAGR
- Marine ToxinUSD 149 mn · 6.0% CAGR
- Fat Modular NutritionUSD 147 mn · 5.0% CAGR
- Cystic Fibrosis Nutrition ProductsUSD 145 mn · 3.5% CAGR
← Cancer Survivorship Nutrition Capsule Endoscope and Workstations →